Bluebird Bio (BLUE) Tops Q2 EPS by 39c

Bluebird Bio (NASDAQ: BLUE) reported Q2 EPS of ($0.06), $0.39 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.15 million.

For earnings history and earnings-related data on Bluebird Bio (BLUE) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital